Peptide receptor radionuclide therapy with 90 Y-DOTATATE/90 Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: Assessment of response, survival and toxicity

British Journal of Cancer

Volumn 108, Issue 7, 2013, Pages 1440-1448

  Vinjamuri, S ^a   Gilbert, T M ^b   Banks, M ^c   McKane, G ^a   Maltby, P ^a   Poston, G ^c   Weissman, H ^c   Palmer, D H ^b   Vora, J ^a   Pritchard, D M ^b   Cuthbertson, D J ^b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; DOTATATE Y 90; DOTATOC Y 90; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; ARTICLE; BLOATING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG RESPONSE; DYSPNEA; FATIGUE; FEMALE; HEMOPTYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

FEMALE; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84876481814     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.103     Document Type: Article

References (28)

1. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Müller HH, Barth P (2008) Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 6: 820-827.
2. Baudin E (2007) Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nat Clin Pract Endocrinol Metab 3: 228-239.
3. Bech PR, Ramachandran R, Dhillo WS, Martin NM, Bloom SR (2012) Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine-and amphetamine-regulated transcript. Clin Chem 58: 941-943.
4. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25: 1760-1764. (Pubitemid 46797958)
5. Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, Mikolajczak R, Pawlak D, Stepien K, Walecki J (2010) Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol 21: 787-794.
6. Davies AH, Larsson G, Ardill J, Friend E, Jones L, Falconi M, Bettini R, Koller M, Sezer O, Fleissner C, Taal B, Blazeby JM, Ramage JK. EORTC Quality of Life Group (2006) Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer 42: 477-484. (Pubitemid 43227926)
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
8. Forrer F, Waldherr C, Maecke HR, Mueller-Brand J (2006) Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 26: 703-707. (Pubitemid 43206037)
9. Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, Cumming P, Bartenstein P, Tiling R, Hacker M (2010) 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51(9): 1349-1356.
10. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Macke H, Rochlitz C, Muller-Brand J, Walter M (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29: 2416-2423.
11. Kulke MH, Mayer RJ (1999) Carcinoid tumors. N Engl J Med 340: 858-868. (Pubitemid 29142631)
12. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC (2011) Future directions in the treatment of neuroendocrine tumors: consensus report of the national cancer institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol 29: 934-943.
13. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26: 2124-2130.
14. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kuda B, de Herder WW, Plöckinger U. and the Mallorca Consensus Conference participants (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs. Neuroendocrinology 90: 220-226.
15. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'Dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP (2005a) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1): 62S-66SS.
16. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders AA, van Eijck CH, Esser J, Kam BL, Krenning EP (2005b) Radiolabelled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23: 2754-2762. (Pubitemid 46179465)
17. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9: 61-72.
18. Mosli HH, Dennis A, Kocha W, Asher LJ, Van Uum SH (2012) Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. J Clin Endocrinol Metab 97: E1731-E1735.
19. Nwosu AC, Jones L, Vora J, Poston GJ, Vinjamuri S, Pritchard DM (2008) Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 98: 1053-1058. (Pubitemid 351399810)
20. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR (1998) Yttrium-90-labelled somatostatin-analogue for cancer. Lancet 351: 417-418.
21. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB. UK and Ireland Neuroendocrine Tumour Society (2011) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61: 6-32.
22. Rolleman E, Valkema R, de Jong M, Kooij P, Krenning E (2003) Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30: 9-15. (Pubitemid 36692887)
23. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36: 147-156. (Pubitemid 43320450)
24. Van Belle Gerald (2002) Statistical rules of thumb. John Wiley and Sons: New Jersey.
25. Vegt E, Wetzels JF, Russel FG, Masereeuw R, Boerman OC, van Eerd JE, Corstens FH, Oyen WJ (2006) Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 47: 432-436. (Pubitemid 46768485)
26. Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, Ng QK, Mäcke HR, Müller-Brand J, Rochlitz C, Briel M, Walter MA (2012) Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 30: 1100-1106.
27. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J (2001) The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12: 941-945. (Pubitemid 32725766)
28. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43: 610-616. (Pubitemid 34507110)